Your browser doesn't support javascript.
loading
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
Wang, Yucai; Tschautscher, Marcella A; Rabe, Kari G; Call, Timothy G; Leis, Jose F; Kenderian, Saad S; Kay, Neil E; Muchtar, Eli; Van Dyke, Daniel L; Koehler, Amber B; Schwager, Susan M; Slager, Susan L; Parikh, Sameer A; Ding, Wei.
Afiliación
  • Wang Y; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Tschautscher MA; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Rabe KG; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
  • Call TG; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Leis JF; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Kenderian SS; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kay NE; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Van Dyke DL; Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA.
  • Koehler AB; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Schwager SM; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Slager SL; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
  • Parikh SA; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Ding W; Division of Hematology, Mayo Clinic, Rochester, MN ding.wei@mayo.edu.
Haematologica ; 105(3): 765-773, 2020 03.
Article en En | MEDLINE | ID: mdl-31197071
The natural history, prognostication and optimal treatment of Richter transformation developed from chronic lymphocytic leukemia (CLL) are not well defined. We report the clinical characteristics and outcomes of a large series of biopsy-confirmed Richter transformation (diffuse large B-cell lymphoma or high grade B-cell lymphoma, n=204) cases diagnosed from 1993 to 2018. After a median follow up of 67.0 months, the median overall survival (OS) was 12.0 months. Patients who received no prior treatment for CLL had significantly better OS (median 46.3 vs. 7.8 months; P<0.001). Patients with elevated lactate dehydrogenase (median 6.2 vs. 39.9 months; P<0.0001) or TP53 disruption (median 8.3 vs. 12.8 months; P=0.046) had worse OS than those without. Immunoglobulin heavy chain variable region gene mutation, cell of origin, Myc/Bcl-2 double expression and MYC/BCL2/BCL6 double-/triple-hit status were not associated with OS. In multivariable Cox regression, elevated lactate dehydrogenase [Hazard ratio (HR) 2.3, 95% Confidence Interval (CI): 1.3-4.1; P=0.01], prior CLL treatment (HR 2.0, 95%CI: 1.2-3.5; P=0.01), and older age (HR 1.03, 95%CI: 1.01-1.05; P=0.01) were associated with worse OS. Twenty-four (12%) patients underwent stem cell transplant (20 autologous and 4 allogeneic), and had a median post-transplant survival of 55.4 months. In conclusion, the overall outcome of Richter transformation is poor. Richter transformation developed in patients with untreated CLL has significantly better survival. Stem cell transplant may benefit select patients.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfoma de Células B Grandes Difuso Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: Haematologica Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfoma de Células B Grandes Difuso Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: Haematologica Año: 2020 Tipo del documento: Article